Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core S&P 500 ETF (IVV) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance

iShares Core S&P 500 ETFTrade
Nuvation Bio Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $779.84 (market cap $899.63B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: iShares Core S&P 500 ETF is far larger — about 526.1× Nuvation Bio Inc. Class A Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.

IVVNUVB
Market Cap
$899.63B$1.71B
Volume
3,643,9265,448,712
Sector
Broad Market / FactorHealth
52-Week High
$782.58$9.54
52-Week Low
$634.93$3.41
Typical Hold Time
46 Days0 Days
Enterprise Value
—$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $780.60, down 0.25% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though RSI suggests potential overbought conditions near-term. The ETF remains a core holding for broad US equity exposure, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment is mixed as valuations attract scrutiny despite index strength.

Outlook remains constructive given the S&P 500's earnings momentum and historical seasonal trends favoring year-end rallies. Key risks include potential profit growth deceleration to 15% in 2027 and concentration in top holdings. The ETF offers diversified exposure to large-cap US equities, with the current level near pivot point support providing a strategic entry zone for long-term investors.

Nuvation Bio Inc. Class A Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IVV
90% Buy10% Sell
Avg holding period · 46 Days
NUVB
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV →

About Nuvation Bio Inc. Class A Common Stock

Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.

Read more on NUVB →